LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

Search

Twist Bioscience Corp

Cerrado

SectorSalud

48.99 3.44

Resumen

Variación precio

24h

Actual

Mínimo

46.95

Máximo

49.59

Métricas clave

By Trading Economics

Ingresos

-3.4M

-31M

Ventas

4.7M

104M

Margen de beneficio

-29.419

Empleados

979

EBITDA

-12M

-33M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+9.54% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

267M

2.9B

Apertura anterior

45.55

Cierre anterior

48.99

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

149 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Twist Bioscience Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

10 feb 2026, 23:26 UTC

Principales Movimientos del Mercado

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10 feb 2026, 22:31 UTC

Ganancias

Correction to America Movil 4Q Profit Article

10 feb 2026, 22:22 UTC

Ganancias

America Movil 4Q Profit Jumps on Lower Financial Costs

10 feb 2026, 23:51 UTC

Charlas de Mercado
Ganancias

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10 feb 2026, 23:42 UTC

Charlas de Mercado

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10 feb 2026, 23:40 UTC

Charlas de Mercado
Ganancias

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10 feb 2026, 23:21 UTC

Charlas de Mercado

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10 feb 2026, 23:21 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

10 feb 2026, 22:17 UTC

Charlas de Mercado

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10 feb 2026, 22:15 UTC

Ganancias

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10 feb 2026, 22:10 UTC

Ganancias

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10 feb 2026, 22:10 UTC

Ganancias

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10 feb 2026, 22:09 UTC

Ganancias

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10 feb 2026, 22:09 UTC

Ganancias

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10 feb 2026, 22:01 UTC

Ganancias

Intact Financial 4Q EPS C$5.24 >IFC.T

10 feb 2026, 21:54 UTC

Ganancias

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10 feb 2026, 21:53 UTC

Ganancias

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10 feb 2026, 21:51 UTC

Ganancias

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10 feb 2026, 21:51 UTC

Ganancias

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 feb 2026, 21:51 UTC

Ganancias

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10 feb 2026, 21:51 UTC

Ganancias

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10 feb 2026, 21:51 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10 feb 2026, 21:50 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10 feb 2026, 21:50 UTC

Ganancias

James Hardie Industries 3Q EPS 12c >JHX

10 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

10 feb 2026, 21:50 UTC

Ganancias

James Hardie Industries 3Q Adj EPS 24c >JHX

10 feb 2026, 21:49 UTC

Ganancias

James Hardie Industries 3Q Sales $1.24B >JHX

10 feb 2026, 21:49 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10 feb 2026, 21:48 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10 feb 2026, 21:47 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Comparación entre iguales

Cambio de precio

Twist Bioscience Corp Esperado

Precio Objetivo

By TipRanks

9.54% repunte

Estimación a 12 meses

Media 52 USD  9.54%

Máximo 58 USD

Mínimo 50 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Twist Bioscience Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

6

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

31.56 / 38.6884Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

149 / 352 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat